Richard E. Champlin

TL;DR: It is concluded that AML/MDS patients receiving pretransplant conditioning treatment with the 4-day regimen may benefit significantly from PK-guided Bu dosing, and could be considered an alternative to fixed-dose delivery since it provides the benefit of precise dose delivery to a predetermined SE without increasing risk of serious toxicity and/or GvHD.

TL;DR: For patients with myeloproliferative disorders and evidence of accelerated disease, HLA‐identical marrow transplantation is well tolerated and can result in an extended disease‐free survival.

TL;DR: Early post-SCT MRD assessment-combined with pre-S CT MRD Assessment, ELN risk category, and age-improves risk stratification for relapse in AML patients post-transplant are combined.

TL;DR: The combination of HyperCVAD regimen with dasatinib is effective in patients with relapsed Ph‐positive ALL and CML‐LB.

TL;DR: Analysis of cells derived from patients classified as either clinically resistant or sensitive to high-dose Bu-based chemotherapy indicated alterations in gene expression that were analogous to those observed in the in vitro model cell lines, confirming the potential clinical relevance of this model for Bu resistance.